|Bid||102.89 x 800|
|Ask||102.79 x 1200|
|Day's range||100.54 - 103.21|
|52-week range||96.67 - 142.60|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||21.52|
|Earnings date||18 Oct 2022 - 24 Oct 2022|
|Forward dividend & yield||1.88 (1.89%)|
|Ex-dividend date||13 Oct 2022|
|1y target est||124.94|
Bulk orders for COVID-19 tests are on the rise as companies brace for a winter surge.
Let's talk about two leaders in their markets and a well-diversified healthcare company with a track record of success. Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating returns for investors for quite a while. Vertex is the global market leader in the treatment of cystic fibrosis (CF).
In the latest trading session, Abbott (ABT) closed at $99.84, marking a -0.83% move from the previous day.